In This Article:
MacroGenics (MGNX) reported $19.35 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 80.5%. EPS of -$0.25 for the same period compares to -$0.75 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $45.26 million, representing a surprise of -57.24%. The company delivered an EPS surprise of -8.70%, with the consensus EPS estimate being -$0.23.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how MacroGenics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
-
Revenue- Product sales, net: $2.16 million versus the three-analyst average estimate of -$2.39 million. The reported number represents a year-over-year change of -54.1%.
-
Revenue- Collaborative and other agreements: $13.68 million versus the two-analyst average estimate of $43 million. The reported number represents a year-over-year change of +153.4%.
-
Revenue- Government agreements: $0.21 million compared to the $0.35 million average estimate based on two analysts. The reported number represents a change of -55.4% year over year.
View all Key Company Metrics for MacroGenics here>>>
Shares of MacroGenics have returned -25.1% over the past month versus the Zacks S&P 500 composite's -7.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
MacroGenics, Inc. (MGNX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).